PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 16106903

[Nitroglycerin-induced headaches].

Gabriella Juhász·Terézia Zsombók·Xénia Gonda·György Bagdy
View original source ↗Export metadata ↓

Abstract

INTRODUCTION: Headache is the most prominent side effect of nitrate therapy. Lack of compliance is usually associated with headache which has a detrimental effect on quality of life. In spite of the high frequency of this adverse effect, the headache characteristics, timing and risk factors are less known. On the other hand, intravenously administered nitroglycerin-induced migraine attack is a common human research model in migraine. AIM OF THE PRESENT STUDY: to evaluate the headaches occurring after administration of therapeutic dose of sublingual nitroglycerin, in migraineurs and controls. METHOD: Twenty-eight female migraine patients without aura and 14 healthy controls received 0.5 mg nitroglycerin. Headache intensity and characteristics have been investigated for 24 hours. RESULTS: two types of headache developed after the nitroglycerin administration: (1) an immediate headache that does not fulfil the criteria for migraine, mild and disappears spontaneously within 1 hour; (2) a typical migraine attack without aura develops several hours after the nitroglycerin administration (mean latency: 250 min), moderate or severe, and warrants antimigraine therapy. The two types of headache developed independently. The nitroglycerin-induced headaches have not been determined solely by the previous migraine diagnosis, although both immediate (p = 0.0045) and typical migraine headache (p = 0.00047) were significantly more frequent among migraineurs compared to controls. Moreover, those control subjects who experienced migraine attacks had predispositions to migraine. Previous results of the authors supported that lower platelet serotonin concentration and higher plasma CGRP concentration, during the headache free period, are risk factors that express greater susceptibility to develop both spontaneous and nitroglycerin-induced migraine attack. CONCLUSION: Authors suggest an accurate exploration of the headache case-history before nitroglycerin treatment. This makes it possible to give proper information to migraine patients and possible migraine patients, and thus suitable treatment can be offered if needed.

Explore related subjects

Administration, SublingualAdultCalcitonin Gene-Related PeptideCase-Control StudiesFemaleHeadacheHumansMaleMiddle AgedMigraine DisordersNitric OxideNitric Oxide SynthaseNitroglycerinPain MeasurementPain ThresholdPatient ComplianceRisk FactorsSeverity of Illness IndexTime FactorsTrigeminal GanglionVasodilator AgentsJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Gabriella Juhász, Terézia Zsombók, Xénia Gonda, György Bagdy. 2004-11-14. [Nitroglycerin-induced headaches].. https://pubmed.ncbi.nlm.nih.gov/16106903/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Impaired vascular function in patients with Fontan circulation.

BACKGROUND: This study was performed to evaluate the endothelial function in Fontan patients, and to investigate the associated factors which influence the endothelial function in these patients. METHODS: Flow mediated dilatation (FMD) and nitroglycerin induced dilatation (NG) of the brachial artery, and intima media thickness (IMT) of common carotid artery (CCA) were measured in nonselected Fontan patients (n=44, age 5 to 29 years, median 14 years, 18 females) by means of high-resolution ultrasound according to the standard protocols. The results were compared to age and sex matched controls (n=25, age 5 to 27 years, median 13 years, 10 females). RESULTS: Fontan patients presented significantly reduced FMD and NG compared with controls (FMD; 6.5+/-2.4 vs. 11.1+/-1.4%, p<0.001, NG; 13.3+/-5.2 vs. 19.4+/-6.2%; p=0.035). Twenty two percent of Fontan patients presented pure endothelial dysfunction, and 34% of patients presented combined endothelial and smooth muscle dysfunction. Although there was no correlation between FMD and IMT, Fontan patients presented increased carotid IMT (0.44+/-0.07 vs. 0.38+/-0.06 mm, p=0.008). In multivariate analysis, duration of exposure to chronic hypoxia was inversely correlated with FMD (p=0.117, hazards ratio=1.294, 95% confidence interval=0.938-1.786). There was higher FMD in patients receiving angiotensin-converting enzyme inhibitors (ACEi) compared with those not receiving ACEi (7.0+/-2.5 vs. 5.5+/-2.2%, p=0.069). CONCLUSIONS: Endothelial dysfunction is more prevalent in Fontan patients compared with healthy controls, and the previous hypoxia is an independent factor. Although it is not statistically significant, those patients on treatment with ACEi seem to have better endothelial function.

Administration, Sublingual↗
PubMed2006

A trial of integrated buprenorphine/naloxone and HIV clinical care.

BACKGROUND: Untreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)-positive patients. Buprenorphine, a partial opioid agonist, is available for maintenance treatment of opioid dependence in HIV specialty settings. We investigated the feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling, into HIV clinical care. METHODS: HIV-positive, opioid-dependent patients were enrolled in a 12-week pilot study and randomized to receive daily buprenorphine/naloxone treatment along with either brief physician management or physician management combined with nurse-administered drug counseling and adherence management. Primary outcomes included treatment retention; illicit drug use, assessed by urine toxicology test and self-report; CD4 lymphocyte counts; and log(10) HIV type 1 (HIV-1) RNA levels. RESULTS: Of the 16 patients who received at least 1 dose of buprenorphine, 13 (81%) completed 12 weeks of treatment. The proportion of opioid-positive weekly urine test results decreased from 100% at baseline to 32% (month 1), 20% (month 2), and 16% (month 3). Only 4 patients reported any opioid use (in the prior 7 days) during the 12-week study. CD4 lymphocyte counts remained stable over the course of the study. The mean log(10) HIV-1 RNA level (+/- standard deviation) declined significantly, from 3.66+/-1.06 log(10) HIV-1 RNA copies/mL at baseline to 3.0+/-0.57 log(10) HIV-1 RNA copies/mL at month 3 (P<.05). No significant differences based on counseling intervention were detected. All 13 patients who completed the study continued to receive treatment in an extension phase of at least 0-15 months' duration. CONCLUSIONS: We conclude that it is feasible to integrate buprenorphine into HIV clinical care for the treatment of opioid dependence. Patients experienced good treatment retention and reductions in their opioid use. HIV biological markers remained stable or improved during buprenorphine/naloxone treatment.

Administration, Sublingual↗